Black Diamond Therapeutics Inc Asset Resilience Ratio
Black Diamond Therapeutics Inc asset resilience ratio. Black Diamond Therapeutics Inc (BDTX) has an Asset Resilience Ratio of 73.03% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BDTX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Black Diamond Therapeutics Inc (2020–2025)
Asset resilience ratio of Black Diamond Therapeutics Inc from 2020 to 2025. This chart shows how Black Diamond Therapeutics Inc's Asset Resilience Ratio has changed over time. Read BDTX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Black Diamond Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BDTX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $91.31 Million | 73.03% |
| Total Liquid Assets | $91.31 Million | 73.03% |
Asset Resilience Insights
- Very High Liquidity: Black Diamond Therapeutics Inc maintains exceptional liquid asset reserves at 73.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Black Diamond Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Black Diamond Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Black Diamond Therapeutics Inc Asset Resilience Ratio by Year (2020–2025)
Black Diamond Therapeutics Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Black Diamond Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.28% | $107.66 Million | $143.01 Million | +24.62pp |
| 2024-12-31 | 50.67% | $62.14 Million | $122.64 Million | +3.26pp |
| 2023-12-31 | 47.41% | $75.18 Million | $158.57 Million | -9.22pp |
| 2022-12-31 | 56.63% | $88.49 Million | $156.25 Million | -1.50pp |
| 2021-12-31 | 58.13% | $143.99 Million | $247.68 Million | -26.94pp |
| 2020-12-31 | 85.07% | $280.46 Million | $329.67 Million | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more